UBS Maintains Buy on CVS Health, Lowers Price Target to $118

Benzinga Newsdesk www.benzinga.com Neutral 51.5%

Neg 0% Neu 51.5% Pos 0%

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $126 to $118.

Comments

No comments yet. Be the first!